All News

Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions
Ref: GlobeNewswire
Tags: Press ReleaseAkcea Therapeutics IonisDyslipidemia Clinical Research (R&D) Medical AffairsAHA Scientific SessionsAKCEA-APO(a)-LRx
DiaMedica Therapeutics Has Applied to List its Common Shares on Nasdaq, Announces Share Consolidation
Ref: GlobeNewswire
Tags: Press ReleaseDiaMedica Corporate Affairs
Angion Biomedica and Sinovant Sciences Enter into Collaboration and License Agreement to Develop BB3 in Greater China
Ref: PR Newswire
Tags: Press ReleaseAngion Biomedica Sinovant Sciences Corporate Affairs LicensingBB3
Medigene Signs Exclusive License Agreement with Leiden University to Develop Novel T Cell Receptor
Ref: Medigene
Tags: Press ReleaseMedigene Corporate Affairs Licensing
Summit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week
Ref: GlobeNewswire
Tags: Press ReleaseSummit TherapeuticsBacterial Infections STDs Clinical Research (R&D) Medical AffairsSMT-571
Eton Pharmaceuticals Announces Pricing of Initial Public Offering
Ref: GlobeNewswire
Tags: Press ReleaseEton Pharmaceuticals Corporate Affairs
Synlogic Presents Data at the 2018 Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
Ref: Business Wire
Tags: Press ReleaseAbbVie Synlogic Clinical Research (R&D) Medical AffairsAASLDSYNB1020
Neon Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Highlights
Ref: GlobeNewswire
Tags: Press ReleaseNeon Therapeutics Corporate Affairs
Urovant Sciences Reports Financial Results for the Second Fiscal Quarter Ended September 30, 2018 and Provides Corporate Update
Ref: Business Wire
Tags: Press ReleaseUrovant Sciences Corporate Affairsvibegron hMaxi-K
Cyclacel Pharmaceuticals Reports Third Quarter 2018 Financial Results
Ref: GlobeNewswire
Tags: Press ReleaseCyclacel Corporate AffairsCYC065 CYC140